Executives On The Move: Changes to Development Posts At Amgen, Orchard Therapeutics, Tilray, Genentech And NGM Biopharma
It’s all about development — Amgen Development VP now CTO at rare disease firm Orchard Therapeutics, and Goldman Sachs exec is chief corporate development officer at pharma/cannabis business Tilray. Meanwhile, Genentech early clinical development VP switches to CMO spot at cardio-metabolic and liver disease company NGM Biopharma.
You may also be interested in...
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Executives On The Move: Boehringer Announces US Promotion, Immatics Chooses A CMO And DalCor Pharma Fills C-Suite Commercial Post
Boehringer Ingelheim announces its BI Pharma president to take helm from retiring US country managing director and chief executive officer. Immunotherapeutics developer Immatics Biotechnologies chooses GSK cell therapy head as CMO, and precision medicine firm DalCor Pharmaceuticals picks a chief commercial officer.
Executives On The Move: Clinical Positions Filled At Gilead, Sanifit and Spectrum, And Ferring Pharma US Officer Is Promoted
Anti-viral pharma Gilead Sciences, vascular calcification treatment firm Sanifit and hematology and oncology drug developer Spectrum Pharmaceuticals each select a new VP, clinical development. Also, to oversee its group in the US, multinational Ferring Pharmaceuticals promotes its US chief commercial officer to president.